Hinge Health, Inc. Q3 FY2026 earnings call

• Financial Momentum: Delivered all-time highs in profitability. LTM calculated billings reached $960 million (up 54% YoY). Free cash flow was $120 million (51% margin).
• Core MSK Leadership: Remains the primary revenue driver. Movement analysis technology and redesigned exercise experiences are improving adherence and consumer-grade experience.
• Migraine Care Expansion: Early access data shows a 23% reduction in monthly migraine days and 28% reduction in duration. Over half of members achieved clinically meaningful changes on HIT-6 scores. Enrollment is tracking expectations, with bulk launch expected in early 2027.
• GI Care Strategy: Leveraging the Cylinder acquisition to build an integrated GI program targeting Summer 2027 launch. Features include AI-powered food/stool analysis and multidisciplinary care teams. Client base grew 40% since acquisition announcement.
• Commercial Growth: Contracted clients reached 3,270 (up 28% YoY). Added three new Fortune 15 clients. SMB segment closed nearly 1 million lives, showing faster sales cycles and higher yields.
• Leadership Transition: President Jim Pursley is stepping back from his operational role at year-end to join the Board of Directors. CCO Aaron Peer will assume leadership of the go-to-market function.

The transcript does not provide a breakdown of revenue by specific product segment (e.g., MSK vs. Migraine vs. GI). The company reports consolidated financials: Revenue was $235 million (up 52% YoY), representing 100% of total reported revenue. Gross margin was 88%. Operating income was $77 million with a 33% operating margin.

• Q4 2026 Revenue: Raised to $249–$251 million (midpoint implies ~46% growth vs. prior year).
• Q4 2026 Operating Income: Guided to $81–$83 million (33% operating margin midpoint).
• Full Year 2026 Revenue: Raised to $879–$881 million (midpoint implies ~50% growth; previously $856–$860 million).
• Full Year 2026 Operating Income: Raised to $266–$268 million (30% operating margin midpoint).
• Key Drivers for Raise: Inclusion of Cylinder net new lives (~25.5M eligible lives end-of-year) and improved yield assumption (4.6%, up from 4.45%).
• Share Count: Expected to remain stable at 85–87 million weighted average diluted shares.

• Hardware Costs & Margins: While gross margins expanded due to reduced hardware costs, future leverage depends on sustaining AI/automation efficiency as scale increases.
• New Program Execution: Migraine and GI programs are early-stage; clinical outcomes and commercial adoption trajectories carry execution risk until full scale in 2027/2028.
• Competitive Landscape: Company acknowledges competitors adding random condition areas but asserts its unified platform provides a differentiated advantage in pricing and integration.

Q: Analyst asked about Hinge Select (surgery) traction on the employer side and network build-out.

A: CEO noted strong client reception, doubling lives since Investor Day. Network includes ~5,500 locations, expanding into surgery via market-by-market contracting. Emphasized complementing health plans rather than competing, focusing on high-quality sites near members. Projected slower initial burn but enduring long-term value.

Q: Analyst inquired about GI integration progress and revenue timing.

A: CEO confirmed operational and product integration is on track, with the integrated app experience targeted for Summer 2027. Clients signed today will be upgraded upon launch. Highlighted 40% growth in GI clients since acquisition announcement, driven by unmet need regarding GLP-1 side effects. Expected significant revenue contribution starting in 2028.

Q: Analyst asked about sustainability of gross margin expansion and care team staffing for 2027.

A: CEO stated gross margin target remains ~85% next year, down from this year's outperformance. Confirmed hiring across the board to meet insatiable demand for MSK, Migraine, and GI care. Asserted that AI and automation will continue to drive leverage in internal operations and care delivery, though hiring is necessary to support volume.

Q: Analyst questioned ASP trends and whether engagement-based pricing would allow for ASP uplift.

A: CFO confirmed ASPs are expected to remain flat in 2026 and 2027. CEO added that ASP increases may occur later (late 2027/2028) as new programs mature and drive deeper engagement, but current focus is on member engagement and clinical outcomes rather than immediate price hikes.

Q: Analyst asked about SMB market dynamics, competitive win-rates, and incremental margins compared to enterprise.

A: CCO highlighted SMB as an underpenetrated market with faster sales cycles and better economics/yields. Noted that TPA/health plan partners are embedding Hinge Health as an opt-out default, providing first-mover advantage. CFO confirmed SMB yields improve operating margins due to quicker launch cycles and lower friction.